Irvine, CA – July 14, 2025 – Johnson & Johnson MedTech, a leader in neurovascular care, announced today its upcoming data presentations and onsite activities at the 2025 Society of NeuroInterventional Surgery (SNIS) 22nd Annual Meeting & Fellows Course July 14-17 in Nashville, Tenn. The company will present data underscoring its commitment to advancing science and device performance in neurovascular intervention.
“At SNIS 2025, we’re proud to bring forward clinical evidence and technologies that reflect our long-standing commitment to neurovascular innovation,” said Christian Cuzick, President, Worldwide Neurovascular, Johnson & Johnson MedTech. “This year marks 25 years of TRUFILL ® n-BCA and a decade of NTI, the scientific research arm of Johnson and Johnson MedTech Neurovascular, that works to understand neurovascular disease, which uniquely informs our R&D process. As we celebrate these milestones, we’re excited to preview the next generation of catheters in our Stroke Solutions portfolio with CEREGLIDE™ 42 and CEREGLIDE™ 57, which are designed to help physicians achieve even greater precision and performance in clot retrieval and which will complement our CEREGLIDE Family.”
Featured posters include:
· Feasibility of Middle Meningeal Artery Embolization with TRUFILL® n-BCA for Refractory Chronic Migraine – MIGRAINE Study
o Presenter: Adam Arthur, MD; Semmes Murphey Foundation (Memphis, Tenn.)
o Monday, July 14, 4:03 pm – 4:11 pm
· Liquid Embolic-Related Microcatheter Retention Rates in Neurovascular Disease: A Systematic Review and Meta-Analysis
o Presenter: Ansaar T. Rai, MD; Professor and Chair, Department of Neuroradiology (West Virginia University)
o E-Poster
In addition to its scientific presentations, Johnson & Johnson MedTech will participate in interactive educational forums and events during SNIS, including:
- Fellows Course Hands-on Labs | Thursday, July 17, 5:30-9 p.m.
- The Women in Neurointervention Discussion | Wednesday, July 16, 5:30-7 p.m.
- SLICE Workshop | Tuesday, July 15 / Wednesday, July 16 / and Thursday, July 17
- EVOLVING STROKE CARE TICI 2b OR NOT 2b | Tuesday, July 15, 6:00 PM at Moto, 1120 McGavock St, Nashville.
- Drs. Jagadeesan, Samaniego and Farhat share their experiences with the full J&J MedTech stroke portfolio: featuring CEREGLIDE 71, CEREGLIDE 92 and EMBOTRAP III.
Cardiovascular Solutions from Johnson & Johnson MedTech
Across Johnson & Johnson, we are tackling the world’s most complex and pervasive health challenges. Through a cardiovascular portfolio that provides healthcare professionals with advanced mapping and navigation, miniaturized tech, and precise ablation we are addressing conditions with significant unmet needs such as heart failure, coronary artery disease, stroke, and atrial fibrillation. We are the global leaders in heart recovery, circulatory restoration and the treatment of heart rhythm disorders, as well as an emerging leader in neurovascular care, committed to taking on two of the leading causes of death worldwide in heart failure and stroke. For more information, visit https://www.jnjmedtech.com/en-US/companies/cerenovus and connect on LinkedIn and X.
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Learn more about our MedTech sector’s global scale and deep expertise in cardiovascular, orthopedics, surgery and vision solutions at https://thenext.jnjmedtech.com. Follow us at @JNJMedTech and on LinkedIn. DePuy Synthes Sales, Inc. d/b/a CERENOVUS and Medical Device Business Services, Inc. are Johnson & Johnson Companies.
Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: uncertainty of commercial success; challenges to patents; competition, including technological advances, new products and patents attained by competitors; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory action; changes to applicable laws and regulations, including global health care reforms; changes in behavior and spending patterns of purchasers of health care products and services; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.
US_NEU_HEMO_403145
(c) Johnson & Johnson and its affiliates 2025
Media contact:
James Alley
Jalley1@its.jnj.com
Investor contact:
Sandra Easton
seaston@its.jnj.com